TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema.

CONCLUSIONS: This protocol delineates a safety study for dupilumab in adult and paediatric patients with atopic eczema, using a standardized methodological approach across several national registries. The protocol could also be used for other novel systemic immunomodulating therapies and could provide licensing and reimbursement authorities, pharmaceutical companies and clinicians with safety evidence from a routine clinical care setting. This article is protected by copyright. All rights reserved.
PMID: 31444799 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - August 23, 2019 Category: Dermatology Authors: Bosma AL, Spuls PI, Garcia-Doval I, Naldi L, Prieto-Merino D, Tesch F, Apfelbacher CJ, Arents BWM, Barbarot S, Baselga E, Deleuran M, Eichenfield LF, Gerbens LAA, Irvine AD, Manca A, Mendes-Bastos P, Middelkamp-Hup MA, Roberts A, Seneschal J, Svensson Å, Tags: Br J Dermatol Source Type: research